AN IN VITRO TEST PREDICTIVE OF THE IN VIVO B CELL RITUXIMAB-TRIGGERED DEPLETION, UNDERLINES THE POTENTIAL THERAPEUTIC INTEREST OF A RECOMBINANT ANTI-CD20 IGA IN B-CLL PATIENTS

被引：0
|
作者：
Congy, N. [1 ]
Ysebaert, L. [2 ]
Apoil, P. [1 ]
Tiraby, G. [3 ]
Drocourt, D. [3 ]
Abbal, M. [1 ]
Blancher, A. [1 ]
机构：
[1] Univ Paul Sabatier, EA 3O34, Toulouse, France
[2] CHU Purpan, INSERM, U563, Toulouse, France
[3] Cayla Invivogen, Toulouse, France
来源：
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL | 2010年 / 95卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1263
引用
收藏
页码：515 / 515
页数：1
相关论文
共 50 条
  • [21] Anti-CD20 and B-Cell Receptor-Mediated Growth Inhibition and Apoptosis: A Preclinical Study of Ibrutinib and Rituximab Combination Therapy in Mantle Cell Lymphoma in Vitro and in Vivo
    Zhang, Liang
    Zhang, Hui
    Zhao, Donglu
    Tsourdinis, George
    Park, Hyebin
    Tamayo, Archito T.
    Pham, Lan V.
    Ford, Richard J.
    Fang, Bingliang
    Wang, Michael
    BLOOD, 2014, 124 (21)
  • [22] The humanized anti-CD20 antibody Rituxan induces apoptosis in B-cell chronic lymphocytic leukemia (B-CLL) cells in-vitro and in-vivo, through a p38 MAP-kinase dependent signaling pathway.
    Pedersen, IM
    Buhl, AM
    Klausen, P
    Geisler, CH
    Jurlander, J
    BLOOD, 2000, 96 (11) : 163A - 163A
  • [23] Subcutaneous anti-CD20 targeted B cell depletion preserves memory B cells and IgG serum levels in patients with relapsing remitting multiple sclerosis
    Haase, Stefanie
    Krickl, Anna-Lena
    Freudenstein, David
    Burner, Felix
    Angstwurm, Klemens
    Lee, De-Hyung
    Linker, Ralf
    MULTIPLE SCLEROSIS JOURNAL, 2023, 29 : 335 - 336
  • [24] Pharmacodynamics of B-Cell Depletion and Pharmacokinetics of the Novel Anti-CD20 Monoclonal Antibody Ublituximab in Patients With Relapsing Multiple Sclerosis
    Fox, E.
    Steinman, L.
    Hartung, H.
    Alvarez, E.
    Qian, P.
    Wray, S.
    Robertson, D.
    Huang, D.
    Selmaj, K.
    Wynn, D.
    Weiss, M. S.
    Bosco, J. A.
    Power, S. A.
    Mok, K. A.
    Lee, L.
    Cree, B. A.
    MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (1_SUPPL) : 68 - 68
  • [25] Differential in vitro and in vivo antitumor effects mediated by anti-CD40 and anti-CD20 monoclonal antibodies against human B-cell lymphomas
    Funakoshi, S
    Longo, DL
    Murphy, WJ
    JOURNAL OF IMMUNOTHERAPY, 1996, 19 (02): : 93 - 101
  • [26] THE NOVEL TYPE II CD20 ANTIBODY GA101 MEDIATES SUPERIOR B CELL DEPLETION IN WHOLE BLOOD FROM HEALTHY VOLUNTEERS AND B-CLL PATIENTS
    Herter, S.
    Del Giudice, I.
    Schmidt, C.
    Fauti, T.
    Klein, C.
    Umana, P.
    Dyer, M. J. S.
    Foa, R.
    Grau, R.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 366 - 366
  • [27] New Potential Therapeutic Approach for the Treatment of B-Cell Malignancies Using Chlorambucil/Hydroxychloroquine- Loaded Anti-CD20 Nanoparticles
    Mezzaroba, Nelly
    Zorzet, Sonia
    Secco, Erika
    Biffi, Stefania
    Tripodo, Claudio
    Calvaruso, Marco
    Mendoza-Maldonado, Ramiro
    Capolla, Sara
    Granzotto, Marilena
    Spretz, Ruben
    Larsen, Gustavo
    Noriega, Sandra
    Lucafo, Marianna
    Mansilla, Eduardo
    Garrovo, Chiara
    Marin, Gustavo H.
    Baj, Gabriele
    Gattei, Valter
    Pozzato, Gabriele
    Nunez, Luis
    Macor, Paolo
    PLOS ONE, 2013, 8 (09):
  • [28] Patterns of hepatitis B reactivation and liver test abnormalities in patients with chronic lymphocytic leukemia (CLL) treated with idelalisib plus an anti-CD20 antibody.
    Zelenetz, Andrew David
    Mato, Anthony R.
    Robak, Tadeusz
    Jones, Jeffrey Alan
    Pagel, John M.
    Barrientos, Jacqueline Claudia
    Brown, Jennifer R.
    Montillo, Marco
    Kipps, Thomas J.
    Dubowy, Ronald
    Xing, Guan
    Li, Julia
    Hillmen, Peter
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [29] AR-SA">B-cell depletion and recovery after treatment with the anti-CD20 monoclonal antibody rituximab in patients with posttransplant lymphoproliferative disorders (PT-LPD).
    Grefer, J
    Oertel, SH
    Hummel, M
    Serke, S
    Reinke, P
    Jonas, S
    Anagnostopoulos, I
    Arnold, R
    Dörken, B
    Riess, H
    BLOOD, 2001, 98 (11) : 242B - 242B
  • [30] Reduction of tumor burden and stabilization of disease by systemic therapy with anti-CD20 antibody (rituximab) in patients with primary cutaneous B-cell lymphoma
    Heinzerling, LM
    Urbanek, M
    Funk, JO
    Peker, S
    Bleck, O
    Neuber, K
    Burg, G
    von den Driesch, P
    Dummer, R
    CANCER, 2000, 89 (08) : 1835 - 1844
12345